ArticleInternal and emergency medicine2019
Safety and efficacy of sucrosomial iron in inflammatory bowel disease patients with iron deficiency anemia.
Article in Internal and emergency medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Management of paediatric ulcerative colitis, part 1: Ambulatory care-An updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organisation.Journal of pediatric gastroenterology and nutrition · 2025Guideline
- Oral Sucrosomial Iron Is as Effective as Intravenous Ferric Carboxy-Maltose in Treating Anemia in Patients with Ulcerative Colitis.Nutrients · 2021Trial
- Comment on García-Erce et al. Iron Deficiency and Oral Treatments: Limitations, Pharmacokinetics, and the Role of Iron Protein Succinylate in Clinical Practice.Journal of clinical medicine · 2026Article
- Iron Deficiency and Oral Treatments: Limitations, Pharmacokinetics, and the Role of Iron Protein Succinylate in Clinical Practice.Journal of clinical medicine · 2026Review
- Comparison of Two Oral Iron Formulations for Iron Deficiency and Iron Deficiency Anemia in Inflammatory Bowel Disease: A Prospective Study.GE Portuguese journal of gastroenterology · 2025Article
- Iron Deficiency and Iron Deficiency Anemia: A Comprehensive Overview of Established and Emerging Concepts.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Oral and Intravenous Iron Therapy.Advances in experimental medicine and biology · 2025Review
- Oral iron supplementation: new formulations, old questions.Haematologica · 2024Review
- SucrosomialPharmaceuticals (Basel, Switzerland) · 2023Review
- Sucrosomial® iron effectiveness in recovering from mild and moderate iron-deficiency anemia in the postpartum period.BMC pregnancy and childbirth · 2023Article
- Effect of Intravenous Iron Administration on Bone Mineral and Iron Homeostasis in Patients with Inflammatory Bowel Disease-Results of a Prospective Single-Centre Study.Journal of personalized medicine · 2023Article
- Gut microbiota-derived short-chain fatty acids regulate gastrointestinal tumor immunity: a novel therapeutic strategy?Frontiers in immunology · 2023Review
- Supplementation with Sucrosomial® iron leads to favourable changes in the intestinal microbiome when compared to ferrous sulfate in mice.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2022Article
- Iron distribution in different tissues of homozygous Mask (msk/msk) mice and the effects of oral iron treatments.American journal of hematology · 2021Article
- Observational
- Iron Therapy in Chronic Kidney Disease: Days of Future Past.International journal of molecular sciences · 2021Review
- Iron Therapy in Inflammatory Bowel Disease.Nutrients · 2020Review
- Oral Iron for IBD Patients: Lessons Learned at Time of COVID-19 Pandemic.Journal of clinical medicine · 2020Review
- Stigmatisation and resilience in inflammatory bowel disease.Internal and emergency medicine · 2020Review
- Iron replacement in inflammatory bowel diseases: an evolving scenario.Internal and emergency medicine · 2019Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Iron deficiency anemia (IDA) is one of the most common complications of inflammatory bowel disease (IBD). We planned a prospective study to address tolerability and efficacy of sucrosomial iron, a new oral formulation of ferric pyrophosphate, in IBD patients. Thirty patients with a confirmed diagnosis of Crohn's Disease (CD) or ulcerative colitis (UC) and mild IDA were enrolled. Patients with severe IBD were excluded. All patients underwent 12 weeks of oral treatment with 30 mg/day of sucrosomial iron. Treatment compliance and adverse events were investigated every 4 weeks. Iron status, hematological parameters and IBD activity scores were determined at baseline and at the end of treatment, as well as serum hepcidin and non-transferrin bound iron (NTBI) levels. Twenty-four (80%) patients took more than 90% of the prescribed regimen. Forty-four adverse events (AEs) were recorded, but none of them is considered certainly or probably related to the study treatment. Interestingly, only eleven gastrointestinal events were recorded in 9 (30%) patients. At the end of treatment, all iron parameters improved significantly and Hb increased in 86% of patients (from 11.67 to 12.37 g/dl, p = 0.001). Serum hepcidin showed a significant increase in 79% of patients and became positively correlated with C-reactive protein (CRP) at the end of the study, while NTBI remained below the detection threshold after iron supplementation. The IBD activity scores improved in both CD and UC. This pilot interventional study supports the therapeutic use of sucrosomial iron in IBD and paves the way for future studies in larger or more difficult IBD populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.